Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
First-Line Nivolumab Plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 TrialEur Urol 2021 Nov 05;[EPub Ahead of Print], L Albiges, NM Tannir, M Burotto, D McDermott, ER Plimack, P Barthélémy, C Porta, T Powles, F Donskov, S George, CK Kollmannsberger, H Gurney, MO Grimm, Y Tomita, D Castellano, BI Rini, TK Choueiri, D Leung, SS Saggi, CW Lee, MB McHenry, RJ Motzer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.